Efficacy of Dolasetron in Patients With Fibromyalgia
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
This study offers a new treatment, dolasetron or ANZEMET ®, which will be administered by
intravenous way once a day during a 4 days Hospitalization.
This study is double blind (neither you nor the physician will know if you are receiving
active study drug or placebo).
Randomisation at the beginning of the study will decide whether you receive active treatment
or its placebo.
This treatment will be renewed after one month, after 2 months and after 3 months.
If the study staff determines that you are eligible and you decide to participate, there will
be approximately 6 study visits in about 9 months. During these visits, you will undergo
routine health exams and complete different kinds of questionnaires.
Following this first period of 3 months, you agree to come back for consultation at month 4,
month 6 and month 12 for monitoring and evaluating the effects of treatment.